A Synthetic MUC1 Anticancer Vaccine Containing Mannose Ligands for Targeting Macrophages and Dendritic Cells
Citations Over TimeTop 12% of 2017 papers
Abstract
A MUC1 anticancer vaccine equipped with covalently linked divalent mannose ligands was found to improve the antigen uptake and presentation by targeting mannose-receptor-positive macrophages and dendritic cells. It induced much stronger specific IgG immune responses in mice than the non-mannosylated reference vaccine. Mannose coupling also led to increased numbers of macrophages, dendritic cells, and CD4+ T cells in the local lymph organs. Comparison of di- and tetravalent mannose ligands revealed an increased binding of the tetravalent version, suggesting that higher valency improves binding to the mannose receptor. The mannose-coupled vaccine and the non-mannosylated reference vaccine induced IgG antibodies that exhibited similar binding to human breast tumor cells.
Related Papers
- → Mannose Ligands for Mannose Receptor Targeting(2024)85 cited
- → Generation of Macrophage Variants With 5-Azacytidine: Selection for Mannose Receptor Expression(1987)62 cited
- → A Synthetic MUC1 Anticancer Vaccine Containing Mannose Ligands for Targeting Macrophages and Dendritic Cells(2017)56 cited
- → Mannose‐specific oligosaccharide recognition by mononuclear phagocytes(1984)85 cited
- → Association of furunculosis and familial deficiency of mannose‐binding lectin(2005)21 cited